A-623
AN-SLE3322
Phase 2 small_molecule completed
Quick answer
A-623 for Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at Santhera Pharmaceuticals (Deutschland) GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Santhera Pharmaceuticals (Deutschland) GmbH
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed